Orange Book Decoded: How to Identify and Forecast High-Value Generic Market Opportunities
What this article covers: How to read the FDA Orange Book like a competitive intelligence tool, not a regulatory checkbox. […]
Drug Patents in New Zealand: The Hard 20-Year Limit That Shapes Every Generic Entry Decision
A complete guide for pharmaceutical executives, IP strategists, generic manufacturers, and investors navigating one of the world’s most distinctive patent
Patent Box Tax Strategy: The Definitive Guide to Pharma IP Tax Optimization
The UK Patent Box slashes the effective corporation tax rate on patented-drug profits from 25% to 10%. That 15-percentage-point gap
Patent Box Tax Strategy: The Definitive Guide to Pharma IP Tax Optimization Read Post »
How 180 Days Can Make or Break a Generic Drug Launch: The ANDA Exclusivity Playbook
Generic drug companies do not compete on science. They compete on timing, legal nerve, and an encyclopedic understanding of a
How 180 Days Can Make or Break a Generic Drug Launch: The ANDA Exclusivity Playbook Read Post »
Find Top Biopharma Talent Before Anyone Else: The Patent-to-Pipeline Hiring Playbook
The most sought-after scientists in biopharma rarely post their resumes to LinkedIn. They don’t have to. Their work announces them
Find Top Biopharma Talent Before Anyone Else: The Patent-to-Pipeline Hiring Playbook Read Post »
Europe’s Divisional Patent Trap: How Big Pharma Delays Generics Without Ever Losing in Court
When a European patent dies — formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal
Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching
When Johnson & Johnson’s multiple myeloma franchise Darzalex (daratumumab) generated roughly $10 billion in global revenue in 2024, it stood
Pharm to Table: Map Supply Chains and Predict Drug Shortages Using Patent Data
We rarely know where our medicines originate. The global pharmaceutical supply chain is an opaque network of chemical synthesis facilities,
Pharm to Table: Map Supply Chains and Predict Drug Shortages Using Patent Data Read Post »
Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors
1. Why Patent Expiry Forecasting Is a Revenue-Critical Discipline ‘Between 2025 and 2030, approximately 190 drugs will lose market exclusivity,
